Immuno-Oncology | Specialty

Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma

October 5th 2017

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma

October 5th 2017

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

Atezolizumab + Bevacizumab in Treatment-Naive mRCC

October 4th 2017

Sunitinib Before Cytoreductive Nephrectomy in mRCC

October 4th 2017

CABOSUN: Upfront Use of Cabozantinib for mRCC

October 4th 2017

CheckMate-214: Nivolumab/Ipilimumab for mRCC?

October 4th 2017

Dr. Welling on the Efficacy of Nivolumab in HCC

October 4th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Emerging Data Show Promise With Immunotherapy Combos in NSCLC

October 3rd 2017

Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.

Standard Biopsies Retain Significant Role in Lung Cancer Care

October 3rd 2017

Philip D. Bonomi, MD, discusses some of the known biomarkers in non-small cell lung cancer (NSCLC), the utilization of PD-L1, and other testing modalities.

Expert Highlights Biological Advancements in Bladder Cancer Field

October 3rd 2017

Brant Inman, MD, discusses the biology of bladder cancer, the evolving role of checkpoint inhibitors, and the future of chemotherapy in the disease.

HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017

Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017

Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017

ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017

Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017